IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1301-1325 out of 1375.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

Public Release: 15-Jan-2015
Science
Study identifies new targeted treatment strategy for some aggressive cancers
Researchers from the Massachusetts General Hospital Cancer Center and Boston University School of Medicine have identified the first potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate. Treatment with a small molecule that blocks a key step in the alternative lengthening of telomeres pathway was able to inhibit the growth and survival of ALT-positive tumor cells
Wellcome Trust, National Institute of Health

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 15-Jan-2015
Molecular Cancer Research
New sequencing technique reveals genetic clues to rare breast tumors
A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.
A. Alfred Taubman Medical Research Institute at the University of Michigan

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 15-Jan-2015
Cell
Live imaging captures how blood stem cells take root in the body
A see-through zebrafish and enhanced imaging provide the first direct glimpse of how blood stem cells take root in the body to generate blood. Reporting in Cell, researchers in Boston Children's Hospital's Stem Cell Research Program describe a surprisingly dynamic system that offers clues for improving bone marrow transplants, and for helping those transplants 'take.' The steps are detailed in an animation narrated by senior investigator Leonard Zon, M.D.
Howard Hughes Medical Institute, National Institutes of Health, American Society of Hematology, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Boston Children's Hospital

Public Release: 14-Jan-2015
Nature Communications
Researchers discover new 'trick' steroids use to suppress inflammation
A new 'trick' steroids use to suppress inflammation, which could be used to make new anti-inflammatory drugs without the harmful side effects of steroids, has been discovered by researchers at Georgia State University.
National Institutes of Health, Georgia Research Alliance, Howard Hughes Medical Institute

Contact: LaTina Emerson
lemerson1@gsu.edu
404-413-1353
Georgia State University

Public Release: 14-Jan-2015
International Journal of Epidemiology
Does screening asymptomatic adults for disease save lives?
A new paper published online today in the International Journal of Epidemiology says that randomized controlled trials -- the gold standard method of evaluation -- show that few currently available screening tests for major diseases where death is a common outcome have documented reductions in disease-specific mortality.

Contact: Kirsty Doole
kirsty.doole@oup.com
44-018-653-55439
Oxford University Press

Public Release: 14-Jan-2015
JAMA Surgery
Patients with advanced colon cancer having less surgery, better survival
The annual rate of primary tumor removal for advanced stage IV colorectal cancer has decreased since 1988 and the trend toward nonsurgical management of the disease noted in 2001 coincides with the availability of newer chemotherapy and biologic treatments, according to a report published online by JAMA Surgery.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
The JAMA Network Journals

Public Release: 14-Jan-2015
Journal of Biological Chemistry
Cone snail venom holds promise for medical treatments for cancer and addiction
While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities.
Australian Research Council, National Institutes of Health

Contact: Gisele Galoustian
ggaloust@fau.edu
561-297-2676
Florida Atlantic University

Public Release: 14-Jan-2015
Clinical Cancer Research
CNIO associates rare gene variants with side effects from chemotherapy with paclitaxel
Variants of the CYP3A4 gene are associated with the appearance of peripheral neuropathy, the most frequent and limiting toxicity for these patients, which includes tingling and pain in the extremities, cramping, muscular weakness and difficulty walking. This is the first genetic marker that predicts severe paclitaxel neurotoxicity, which would allow for the individualization of therapies for this patient group. One out of every 35 people in Spain carries these variants, a frequency higher than populations in other geographical areas.

Contact: Vanessa Pombo
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 14-Jan-2015
JAMA Surgery
MD Anderson study finds patients with metastatic colorectal cancer having less surgery
With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors, according to research from The University of Texas MD Anderson Cancer Center.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 14-Jan-2015
Journal of Clinical Investigation
Mutations linked to repair of chromosome ends may make emphysema more likely in smokers
Mutations in a gene that helps repair damaged chromosome ends may make smokers -- especially female smokers -- more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer Center researchers.
National Institutes of Health, Mary Beryl Patch Turnbull Scholar Program, Flight Attendant Medical Research Institute, Commonwealth Foundation

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 14-Jan-2015
World Economic Forum Annual Meeting 2015
World leaders gathering at Davos face calls for bold action to turn the tide on cancer
World leaders will face calls for bold action to respond to the rising human and economic toll of cancer when they meet in Davos at this year's World Economic Forum. Two sessions have been scheduled where international political, civic and business leaders have the chance to discuss how they can work with the cancer community to turn the tide on cancer: Cancer Pathway to a Cure and Globalization of Non-Communicable Diseases.

Contact: Corinne Hall
chall@eso.net
0039-028-546-4522
European School of Oncology

Public Release: 14-Jan-2015
Molecular Pharmacology
Scientists develop novel platform for treatment of breast, pancreatic cancer
Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers.
NIH/National Institute of Mental Health, NIH/National Cancer Institute

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute

Public Release: 13-Jan-2015
Journal of Community and Supportive Oncology
Clinical trial shows benefits of animal-assisted therapy in adult cancer patients undergoing complex cancer treatment with chemotherapy and radiation therapy
Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was made available this week in the Journal of Community and Supportive Oncology.
Good Dog Foundation, Pfeizer

Contact: Lucia Lee
lucia.lee@mountsinai.org
917-837-8914
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 13-Jan-2015
JAMA
Breast cancer diagnoses, survival varies by race, ethnicity
Among nearly 375,000 US women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the Jan. 13 issue of JAMA.

Contact: Julie Saccone
julie.saccone@wchospital.ca
416-323-6400
The JAMA Network Journals

Public Release: 13-Jan-2015
PeerJ
Can inhaled oxygen cause cancer?
The ancient physician/alchemist, Paracelsus, said: 'The dose makes the poison.' According to a new study published in PeerJ, even oxygen may fall prey to the above adage. While essential to human life, aspects of oxygen metabolism may promote cancer. Capitalizing on the inverse relationship of oxygen concentration with elevation, researchers found lower rates of lung cancer at higher elevations, a trend that did not extend to non-respiratory cancers, suggesting that carcinogen exposure occurs via inhalation.

Contact: Kamen Simeonov
kamen.simeonov@gmail.com
304-685-3206
PeerJ

Public Release: 13-Jan-2015
Cancer Research
New target identified for potential brain cancer therapies
Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute for Molecular Medicine have identified a new protein-protein interaction that could serve as a target for future therapies for the most common form of brain cancer, glioblastoma multiforme.
National Institutes of Health, National Foundation for Cancer Researcher, James S. McDonnell Foundation, VCU Massey Cancer Center

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 13-Jan-2015
Lancet Haematology
New test helps guide treatment for bone marrow transplant patients with graft vs. host disease
Innovative scoring system uses 'Ann Arbor raft versus host disease score' to better predict how patients will respond, minimize side effects
NIH/National Cancer Institute, NIH/National Heart, Lung, and Blood Institute, NIH/National Institute of Allergy and Infectious Diseases, Doris Duke Charitable Fund, American Cancer Society, Judith Devries Fund

Contact: Mary Masson
mfmasson@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 13-Jan-2015
Journal of Interferon & Cytokine Research
Do cytokines have a role in the initiation and progression of breast cancer?
Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such as interleukin and transforming growth factor-β play in breast cancer initiation, protection, and metastasis. A comprehensive overview of this new knowledge and its potential to lead to novel therapeutic approaches is presented in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 13-Jan-2015
Clinical Cancer Research
Tumor micro-environment is a rough neighborhood for nanoparticle cancer drugs
Nanoparticle drugs -- tiny containers packed with medicine and with the potential to be shipped straight to tumors -- were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill

Public Release: 13-Jan-2015
Journal of American College of Surgeons
UCLA researchers develop new tool to predict postoperative liver cancer recurrence after transplant
University of California Los Angeles transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions.

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-2262
University of California - Los Angeles Health Sciences

Public Release: 12-Jan-2015
Cancer
From sexual dysfunction to anxiety, many cancer survivors struggle with post treatment
Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment. From physical problems such as sexual dysfunction to anxiety about getting cancer again survivors continue to fight long after the actual disease is defeated. That's the conclusion of a study led by University of Central Florida social work professor Mary Ann Burg.

Contact: Zenaida Gonzalez Kotala
zenaida.kotala@ucf.edu
407-823-6120
University of Central Florida

Public Release: 12-Jan-2015
Experimental Hematology
Researchers discover new therapeutic target for treatment of acute myeloid leukemia
A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment. The scientists discovered that STAT3, a molecule which has the potential to cause cancer, associates with and regulates the levels of PRL-3, a gene which has been implicated in various types of cancers.

Contact: Kimberley Wang
kimberley.wang@nus.edu.sg
National University of Singapore

Public Release: 12-Jan-2015
Oncogenesis
Beyond prevention: Sulforaphane may find possible use for cancer therapy
New research has identified one of the key cancer-fighting mechanisms for sulforaphane, and suggests that this much-studied phytochemical found in broccoli and other foods may be able to move beyond cancer prevention and toward therapeutic use for advanced prostate cancer.
National Institutes of Health

Contact: Emily Ho
Emily.ho@oregonstate.edu
541-737-9559
Oregon State University

Public Release: 12-Jan-2015
Cancer Discovery
Moffitt researchers discover mechanism leading to drug resistance, metastasis in melanoma
Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs. However, patients often develop resistance to these targeted therapies, resulting in more aggressive cells that can spread to other sites or cause regrowth of primary tumors.
National Insitutes of Health, Melanoma and Sarcoma Groningen Foundation, Joanna M. Nicolay Melanoma Foundation.

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 12-Jan-2015
Journal of Clinical Investigation
CNIO researchers discover 1 of the genetic pieces of bladder cancer
Notch genes protect against bladder cancer, whilst in other tumors they act as oncogenes. Researchers warn that drugs that deactivate Notch in a non-specific manner could increase the risk of developing bladder cancer. Bladder cancer is the fifth most frequent cancer among men in developed countries.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Showing releases 1301-1325 out of 1375.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

  Search News Releases

     

 

EurekAlert!